公开(公告)号：US12129493B2

公开(公告)日：2024-10-29

申请号：US17200715

申请日：2021-03-12

Applicant: The Regents of the University of California

Inventor： Jing Huang ,  Zhennan Liu ,  Douglas S. Clark ,  Jay D Keasling ,  Aindrila Mukhopadhyay ,  John F. Hartwig

IPC: C12N5/10 ,  C07D487/22 ,  C12N9/02

CPC classification number: C12N5/10 ,  C07D487/22 ,  C12N9/0069 ,  C12N2510/00

Abstract: The present invention provides for a genetically modified host cell capable of producing an unnatural compound, such as terpenoid, comprising a P450 enzyme comprising an artificial cofactor, and the host cell is capable of uptaking the artificial cofactor by comprising a heterologous heme transport transmembrane protein, or homologue thereof.

公开(公告)号：US20240317863A1

公开(公告)日：2024-09-26

申请号：US18637522

申请日：2024-04-17

Applicant: Oricell Therapeutics Co., Ltd.

Inventor： Bohua LI ,  Huajing WANG ,  Xiaowen HE

IPC: C07K16/28 ,  A61K31/713 ,  A61K39/00 ,  A61P35/00 ,  C12N5/10 ,  C12N15/63

CPC classification number: C07K16/2827 ,  A61K31/713 ,  A61P35/00 ,  C07K16/2878 ,  C07K16/2896 ,  C12N5/10 ,  C12N15/63 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76

Abstract: An antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. The antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody may be used in the prevention and treatment of tumors.

公开(公告)号：US20240307451A1

公开(公告)日：2024-09-19

申请号：US18737778

申请日：2024-06-07

Applicant: NOILE-IMMUNE BIOTECH, INC.

Inventor： Koji TAMADA ,  Yukimi SAKODA ,  Hidenobu ISHIZAKI

IPC: A61K35/17 ,  A61K39/00 ,  C07K14/54 ,  C07K14/725 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/09 ,  C12N15/79

CPC classification number: A61K35/17 ,  A61K39/0011 ,  C07K14/5418 ,  C07K14/7051 ,  C12N5/0636 ,  C12N5/10 ,  C12N15/09 ,  C12N15/79

Abstract: The present disclosure provides an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. The present disclosure also provides an isolated immune cell which expresses a receptor, interleukin-7, and chemokine (C-C motif) ligand 19.

公开(公告)号：US20240301353A1

公开(公告)日：2024-09-12

申请号：US18575460

申请日：2022-06-30

Applicant: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY ,  KYOTO UNIVERSITY

Inventor： Naoya TAKAYAMA ,  Koji ETO ,  Sou NAKAMURA ,  Sudip Kumar PAUL

IPC: C12N5/0786 ,  C12N5/10

CPC classification number: C12N5/0645 ,  C12N5/10 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2510/04

Abstract: The present invention relates to a method for improving proliferative property of a CMP or a myeloid progenitor cell, including a step of forcibly expressing a MYC family gene and BMI1 gene in any cell in the process of differentiation from a hematopoietic progenitor cell into a myeloid progenitor cell, wherein the myeloid progenitor cell is a progenitor cell of macrophage, dendritic cell, granulocyte, erythroblast, or erythrocyte.

公开(公告)号：US12071478B2

公开(公告)日：2024-08-27

申请号：US16331171

申请日：2017-09-07

Applicant: Daiichi Sankyo Company, Limited

Inventor： Ryuta Mukasa ,  Kensuke Nakamura ,  Sumie Muramatsu ,  Naoyuki Makita

IPC: A61P21/00 ,  A61K31/56 ,  A61K39/00 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/16 ,  A61P7/04 ,  A61P7/06 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/04 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K16/28 ,  C07K16/46 ,  C12N5/10 ,  C12N15/09 ,  A61K35/12

CPC classification number: C07K16/2803 ,  A61K31/56 ,  A61K39/0008 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/16 ,  A61P7/04 ,  A61P7/06 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P21/04 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K16/28 ,  C07K16/46 ,  C12N5/10 ,  C12N15/09 ,  A61K2035/122 ,  A61K2039/505 ,  A61K2039/577 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided are methods for treatment or prevention of an autoimmune disease that comprise administering a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.

公开(公告)号：US12063915B2

公开(公告)日：2024-08-20

申请号：US17031255

申请日：2020-09-24

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Lynn Macdonald ,  Andrew J. Murphy ,  Naxin Tu ,  Cagan Gurer

IPC: A01K67/0278 ,  C07K14/705 ,  C12N5/0735 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/85 ,  C07K14/73 ,  C07K14/74

CPC classification number: A01K67/0278 ,  C07K14/70517 ,  C12N5/0606 ,  C12N5/0636 ,  C12N5/10 ,  C12N15/8509 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2267/03 ,  C07K14/70514 ,  C07K14/70539 ,  C07K2319/00 ,  C12N2517/02

Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human T cell co-receptor polypeptides (e.g., CD4, CD8α, CD8β), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.

公开(公告)号：US20240261329A1

公开(公告)日：2024-08-08

申请号：US17798719

申请日：2021-02-05

Applicant: Sichuan University

Inventor： Wei WANG ,  Yuquan WEI

IPC: A61K35/17 ,  A61K39/00 ,  C07K14/42 ,  C07K16/28 ,  C07K16/32 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/86

CPC classification number: A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464406 ,  A61K39/464412 ,  C07K14/42 ,  C07K16/2803 ,  C07K16/32 ,  C12N5/0636 ,  C12N5/10 ,  C12N15/86 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  C07K2317/622 ,  C12N2510/00 ,  C12N2740/15043

Abstract: The present invention belongs to the field of biomedicine, and particularly relates to a chimeric antigen receptor and use thereof. The present invention provides a novel chimeric antigen receptor, comprising an extracellular domain, a transmembrane domain and an intracellular domain, wherein the transmembrane domain and the intracellular domain of the chimeric antigen receptor form a costimulatory signaling domain, and the costimulatory signaling domain comprises a full length or a fragment of an amino acid sequence encoding a reverse dectin-1. Experiments prove that novel CAR-T cells provided by the present invention are effective against a variety of solid tumors and hematological malignancies.

公开(公告)号：US12053524B2

公开(公告)日：2024-08-06

申请号：US17402460

申请日：2021-08-13

Applicant: CENTRE FOR DRUG RESEARCH AND DEVELOPMENT ,  THE UNIVERSITY OF BRITISH COLUMBIA

Inventor： Kelley Marshall McNagny ,  Calvin D. Roskelley ,  Michael R. Hughes ,  Diana Canals Hernaez ,  Klas Ola Blixt ,  John Stephen Babcook ,  Christopher John Bond ,  Ismael Samudio ,  Jan Peter Bergqvist ,  Katherine Grace MacDonald ,  Anna Von Rossum ,  Bradley John Hedberg ,  Pamela Megan Dean

IPC: A61K39/00 ,  A61K35/17 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C12N5/10

CPC classification number: A61K39/39558 ,  A61K35/17 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6817 ,  A61K47/6849 ,  A61K47/6851 ,  A61P35/00 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K16/28 ,  C07K16/30 ,  C07K16/3076 ,  C12N5/10 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/41

Abstract: The present invention is directed to anti-podocalyxin antibodies, compositions comprising the same, and methods of using such antibodies and compositions for the prevention, diagnosis and treatment of cancer.

公开(公告)号：US20240228662A9

公开(公告)日：2024-07-11

申请号：US18235550

申请日：2023-08-18

Applicant: GENMAB A/S

Inventor： Michel DE WEERS ,  Yvo GRAUS ,  Judith OPRINS ,  Paul PARREN ,  Jan VAN DE WINKEL ,  Martine VAN VUGT

IPC: C07K16/40 ,  A61K39/395 ,  A61K49/00 ,  C07K14/705 ,  C07K16/28 ,  C12N5/10 ,  C12N15/63 ,  G01N33/566

CPC classification number: C07K16/40 ,  A61K39/3955 ,  A61K49/0004 ,  C07K14/70596 ,  C07K16/2896 ,  C12N5/10 ,  C12N15/63 ,  G01N33/566 ,  A61K2039/505 ,  C07K2317/34

Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

公开(公告)号：US20240226157A1

公开(公告)日：2024-07-11

申请号：US18424245

申请日：2024-01-26

Applicant: Yamaguchi University

Inventor： Koji Tamada ,  Yukimi Sakoda ,  Keishi Adachi

IPC: A61K35/17 ,  A61K39/00 ,  C07K14/54 ,  C07K14/725 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/09 ,  C12N15/79

CPC classification number: A61K35/17 ,  A61K39/0011 ,  C07K14/5418 ,  C07K14/7051 ,  C12N5/0636 ,  C12N5/10 ,  C12N15/09 ,  C12N15/79

Abstract: It is to provide an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. An immunocompetent cell expressing a cell surface molecule specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19 is generated. Preferably, the cell surface molecule specifically recognizing a cancer antigen is T cell receptor specifically recognizing the cancer antigen, and the immunocompetent cell is a T cell.